VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the European Patent Office (EPO) has issued a Decision to Grant European Patent No. 4539857 covering the Company's proprietary sublingual cladribine oral thin film (ODF) drug delivery technology. The grant will take effect upon publication of the mention of grant in the European Patent Bulletin on March 11, 2026 (Bulletin 26/11). Upon assignment in designated jurisdictions, the patent will ...
[ more ]
